• FDA Approves Crysvita for Treatment of Tumor-Induced Osteomalacia (TIO)

    Date: June 24, 2020

     

    The U.S. Food and Drug Administration (FDA) approved Crysvita (burosumab) for treatment of hypophosphatemia in tumor-induced osteomalacia (TIO), a rare disease caused by slow-growing tumors that produce excess levels of FGF23 . Crysvita, developed by Ultragenyx, is the first FDA-approved non-surgical treatment option for those with TIO, where in approximately half the cases, surgical removal of the tumors is not possible.

    For more information,  please click here

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Policies and Procedures for more details